Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 32Active not recruiting 20Recruiting 16Terminated 11Withdrawn 3Unknown 2Not yet recruiting 2Suspended 1Enrolling by invitation 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Thoracic 31Gastrointestinal 31Dermatologic 25Genitourinary 13Head & Neck 8Breast 8Tumor-Agnostic 6Lymphoid 6Sarcoma 3Other solid neoplasm 3Other hematologic neoplasm 3Gynecologic 2Endocrine 2CNS 2NET 1

Conditions

Brain Neoplasms 2

Interventions

Temozolomide 66Radiotherapy 52Carboplatin 25Bevacizumab 21Cisplatin 19Radiosurgery 18Vincristine 17Etoposide 17Cyclophosphamide 17Surgical Procedures, Operative 13Magnetic Resonance Spectroscopy 13Chemotherapy, Adjuvant 11Melphalan 10Lomustine 10Drug Therapy 10Filgrastim 9Erlotinib Hydrochloride 9apatinib 8Pemetrexed 83-Iodobenzylguanidine 8anlotinib 7Radiation 7Peripheral Blood Stem Cell Transplantation 7Methotrexate 7Thiotepa 6Isotretinoin 6Irinotecan 6Ifosfamide 6Doxorubicin 6Carmustine 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Nivolumab × CNS × Clear all
NCT03458455 2023-11-01

TREATMENT

Oslo University Hospital

Unknown
200 enrolled
CNS

Brain Neoplasms

NCT02460068 2015-06-02

NIBIT-M2

Italian Network for Tumor Biotherapy Foundation

Phase 3 Unknown
168 enrolled
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡